EW Stock Recent News

Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide an update with respect to its previously announced return of capital by way of an approximate $2,714,570 reduction in stated capital of the Company (the "Capital Reduction") and related distribution to the holders of common shares of the Company of a portion of the Company's cash in the amount of $0.03 per common share (the "Special Distribution"). Further to its news release of September 5, 2025, and in accordance with the special resolution passed by the shareholders, the Special Distribution will be paid by the Company's paying agent, Computershare Investor Services Inc. (the "Paying Agent").

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that at the Annual and Special Meeting of Shareholders of the Company (the "Meeting") held on September 5, 2025, the shareholders re-elected Nick DeMare, Mark T. Brown and Kevin William Haney to the board of directors (the "Board").

In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals and never achieve them.

MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless of symptoms. The guidelines enable a proactive approach to disease management and underscore that intervention should be considered for asymptomatic patients, regardless of heart function, which is a meaningful step forward from the prior practice of “watchful waiting.” Th.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be ba.

Investors can contact the law firm at no cost to learn more about recovering their losses  ​

Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards (EW) To Contact Him Directly To Discuss Their Options

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robust pipeline, and potential to triple revenues by 2030.

IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.

The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.